Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

2.96
+0.21007.64%
Post-market: 3.010.0500+1.69%18:00 EST
Volume:132.51K
Turnover:386.39K
Market Cap:98.80M
PE:-8.79
High:3.00
Open:2.80
Low:2.77
Close:2.75
52wk High:5.46
52wk Low:2.33
Shares:33.38M
Float Shares:30.46M
Volume Ratio:0.69
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3367
EPS(LYR):-0.3367
ROE:-67.17%
ROA:-38.83%
PB:6.52
PE(LYR):-8.79

Loading ...

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 04

Anixa Biosciences Receives USAN Council Approval for CAR-T Therapy Name

Reuters
·
Feb 02

Anixa Biosciences Inc - Approved 'Liraltagene Autoleucel' for Fshr-Targeted CAR-T Therapy

THOMSON REUTERS
·
Feb 02

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for Its CAR-T Therapy, a Key Step Toward Future Commercialization

THOMSON REUTERS
·
Feb 02

Insider Move: Anixa Biosciences Director Makes Bold New Bet on the Stock

TIPRANKS
·
Jan 30

Anixa Biosciences Director Arnold M. Baskies Reports Acquisition of Common Shares

Reuters
·
Jan 29

Anixa Biosciences granted patent for breast cancer vaccine technology in Mexico

TIPRANKS
·
Jan 27

Anixa Biosciences Receives Notice of Allowance From Mexican Institute of Industrial Property (Impi) for Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
Jan 27

Anixa Biosciences posts FY2025 interest income of USD 0.7 million, down 41 percent

Reuters
·
Jan 13

Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial

Reuters
·
Dec 15, 2025

Anixa Biosciences Announces Transfer of Ind for Breast Cancer Vaccine From Cleveland Clinic

THOMSON REUTERS
·
Dec 15, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:41 AM

Reuters
·
Dec 12, 2025

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 12, 2025

Anixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine

Reuters
·
Dec 12, 2025

Anixa Biosciences Inc - Vaccine Safe and Well Tolerated at Maximum Dose

THOMSON REUTERS
·
Dec 12, 2025

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

THOMSON REUTERS
·
Dec 12, 2025

Anixa Biosciences CEO to Join Water Tower Research Fireside Chat

Reuters
·
Dec 10, 2025

Anixa Biosciences Secures WHO Approval for CAR-T Therapy Name

Reuters
·
Nov 17, 2025

Anixa Biosciences Announces World Health Organization (Who) Approval of International Non-Proprietary Name for Its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

THOMSON REUTERS
·
Nov 17, 2025

Anixa Biosciences CEO to Join Water Tower Research Fireside Chat

Reuters
·
Nov 10, 2025